{"id":46466,"title":"[Diagnosis, treatment, and follow-up of hepatitis C-virus related liver disease. Hungarian national consensus guideline].","abstract":"Magyarországon 70 000 egyén lehet fert?zött hepatitis C-vírussal, többségük nem tud fert?zöttségér?l. A fert?zés id?ben történ? felfedezése és meggyógyítása a beteg szempontjából a munkaképesség meg?rzését, az életmin?ség javulását, a májzsugor és a májrák megel?zését, valamint a betegségmentes várható élettartam meghosszabbodását, míg a beteg környezete és a társadalom szempontjából a továbbfert?zés veszélyének megállítását, a kés?bbi súlyos májbetegségekb?l adódó egészségügyi ráfordításigény jelent?s csökkenését jelenti. A 2003 óta alkalmazott pegilált interferon+ribavirin kett?s kezeléssel a korábban terápiában nem részesült betegek 40–45%-a, a sikertelenül kezeltek 5–21%-a gyógyítható meg. 2011-ben a korábbiaknál lényegesen hatékonyabb, két új, direkt antivirális hatású proteázgátló szer került forgalomba (boceprevir és telaprevir). A két új szer jelent?sen növeli a fert?zés sikeres gyógyításának esélyét, mindkét fenti betegcsoportban (63–75%, illetve 59–66%). A készítmények – a legrászorultabb beteg számára – 2013. május 1. óta hazánkban is finanszírozottá váltak. A kezelés indikációja – az ellenjavallatok kizárása után – a vírusnukleinsav és a májbetegség kimutatása. Utóbbit a gyulladásos aktivitás és/vagy a májfibrosis mértéke (stádium) jellemzi. A kivizsgálás és a kezelés során fontos a virológiai vizsgálatok gyors és megbízható elvégzése. A stádium meghatározására az invazív májbiopszia mellett a nem invazív tranziens elasztográfia és validált biokémiai fibroteszt módszerek alkalmazhatók. A szakmailag indokolt kezelés finanszírozási korlátok figyelembevételével, a rászorultság sorrendjében kerül engedélyezésre. Ennek alapja az úgynevezett Prioritási Index, amely a májbetegség stádiuma mellett figyelembe veszi a betegség aktivitását, a kezelés sikerességének várható esélyét és további meghatározott speciális szempontokat is. Hazánkban a korábban még nem kezeltek terápiájában továbbra is a pegilált interferon és ribavirin kett?s kombináció, míg a korábban sikertelenül kezelt, 1-es genotípussal fert?zött betegek proteázgátló alapú hármas kombinációban részesülnek. Nem 1-es genotípus esetén a proteázgátlók nem használhatók. A terápia id?tartama 1-es genotípus esetén általában 48 hét, megfelel? vírusválasz mellett, cirrhosis hiányában rövidebb kezelés is elegend? lehet. 2-es és 3-as genotípus esetén a kezelés id?tartama leggyakrabban 24 hét, míg 4-es vagy ismeretlen genotípus esetén a gyógyszerek adásának id?tartama 24/48/72 hetes, a terápiás válasz függvényében. Fokozott figyelmet kell fordítani a mellékhatásokra, a gyógyszerkölcsönhatásokra és a rezisztencia lehet?ségére. Orv. Hetil., 2014, 155(Szuppl. 2), 3–24.Approximately 70 000 people are infected with hepatitis C virus in Hungary, more than half of whom are not aware of their infection. Early recognition and effective treatment of related liver injury may prevent consequent advanced liver diseases (liver cirrhosis and liver cancer) and its complications. In addition, it may increase work productivity and life expectancy of infected individual, and can prevent further viral transmission. Early recognition can substantially reduce the long term financial burden of related morbidity from socioeconomic point of view. Pegylated interferon + ribavirin dual therapy, which is available in Hungary since 2003, can kill the virus in 40-45% of previously not treated (naïve), and in 5-21% of previous treatment-failure patients. Addition of two direct acting first generation protease inhibitor drugs (boceprevir and telaprevir) to the dual therapy increased the chance of sustained clearance of virus to 63-75% and 59-66%, respectively. These two protease inhibitor drugs are available and financed for a segment of Hungarian patients since May 2013. Indication of therapy includes exclusion of contraindications to the drugs and demonstration of viral replication with consequent liver injury, i.e., inflammation and/or fibrosis in the liver. For initiation of treatment as well as for on-treatment decisions accurate and timely molecular biology tests are mandatory. Staging of liver damage (fibrosis) non-invasive methods (transient elastography and biochemical methods) are acceptable to avoid concerns of patients related to liver biopsy. Professional decision for treatment is balanced against budget limitations in Hungary, and priority is given to those with urgent need using a national Priority Index system reflecting stage of liver disease as well as additional factors (activity and progression of liver disease, predictive factors and other special circumstances). All naïve patients are given a first chance with dual therapy. Those with genotype 1 infection and with on-treatment or historic failure to dual therapy are eligible to receive protease inhibitor based triple therapy provided, they reach financial cutoff eligibility based on Priority Index. Duration of therapy is usually 48 weeks in genotype 1 with a response-guided potential to reduce duration for non-cirrhotic patients. Patients with non-1 genotypes are treated with dual therapy (without protease inhibitors) for a genotype and response driven duration of 16, 24, 48, or 72 week. Careful monitoring for early recognition and management of side-effects as well as viral response and potential breakthrough during protease-inhibitor therapy are recommended.","date":"2014-03-17","categories":"Digestive System Diseases","split":"train","url":"http://www.ncbi.nlm.nih.gov/pubmed/24631886","annotations":[{"name":"Ribavirin","weight":0.893958,"wikipedia_article":"http://en.wikipedia.org/wiki/Ribavirin"},{"name":"Hepatitis C","weight":0.889807,"wikipedia_article":"http://en.wikipedia.org/wiki/Hepatitis_C"},{"name":"Liver biopsy","weight":0.866583,"wikipedia_article":"http://en.wikipedia.org/wiki/Liver_biopsy"},{"name":"Protease inhibitor (pharmacology)","weight":0.843153,"wikipedia_article":"http://en.wikipedia.org/wiki/Protease_inhibitor_(pharmacology)"},{"name":"Cirrhosis","weight":0.821349,"wikipedia_article":"http://en.wikipedia.org/wiki/Cirrhosis"},{"name":"Biopsy","weight":0.816757,"wikipedia_article":"http://en.wikipedia.org/wiki/Biopsy"},{"name":"Genotype","weight":0.80522,"wikipedia_article":"http://en.wikipedia.org/wiki/Genotype"},{"name":"Biochemistry","weight":0.804197,"wikipedia_article":"http://en.wikipedia.org/wiki/Biochemistry"},{"name":"Protease","weight":0.802603,"wikipedia_article":"http://en.wikipedia.org/wiki/Protease"},{"name":"Cancer","weight":0.801843,"wikipedia_article":"http://en.wikipedia.org/wiki/Cancer"},{"name":"Fibrosis","weight":0.801843,"wikipedia_article":"http://en.wikipedia.org/wiki/Fibrosis"},{"name":"Hepatitis","weight":0.797255,"wikipedia_article":"http://en.wikipedia.org/wiki/Hepatitis"},{"name":"Interferon","weight":0.796849,"wikipedia_article":"http://en.wikipedia.org/wiki/Interferon"},{"name":"Diagnosis","weight":0.787846,"wikipedia_article":"http://en.wikipedia.org/wiki/Diagnosis"},{"name":"Hepatotoxicity","weight":0.765521,"wikipedia_article":"http://en.wikipedia.org/wiki/Hepatotoxicity"},{"name":"PEGylation","weight":0.74879,"wikipedia_article":"http://en.wikipedia.org/wiki/PEGylation"},{"name":"Liver","weight":0.746246,"wikipedia_article":"http://en.wikipedia.org/wiki/Liver"},{"name":"Inflammation","weight":0.745929,"wikipedia_article":"http://en.wikipedia.org/wiki/Inflammation"},{"name":"Molecular biology","weight":0.744544,"wikipedia_article":"http://en.wikipedia.org/wiki/Molecular_biology"},{"name":"Infection","weight":0.72904,"wikipedia_article":"http://en.wikipedia.org/wiki/Infection"},{"name":"Life expectancy","weight":0.717012,"wikipedia_article":"http://en.wikipedia.org/wiki/Life_expectancy"},{"name":"Virus","weight":0.709797,"wikipedia_article":"http://en.wikipedia.org/wiki/Virus"},{"name":"Disease","weight":0.701843,"wikipedia_article":"http://en.wikipedia.org/wiki/Disease"},{"name":"Morbidity","weight":0.696601,"wikipedia_article":"http://en.wikipedia.org/wiki/Morbidity"},{"name":"Drug","weight":0.685154,"wikipedia_article":"http://en.wikipedia.org/wiki/Drug"},{"name":"Hepatitis C virus","weight":0.665395,"wikipedia_article":"http://en.wikipedia.org/wiki/Hepatitis_C_virus"},{"name":"Therapy","weight":0.654651,"wikipedia_article":"http://en.wikipedia.org/wiki/Therapy"},{"name":"Liver disease","weight":0.64493,"wikipedia_article":"http://en.wikipedia.org/wiki/Liver_disease"},{"name":"Biology","weight":0.643949,"wikipedia_article":"http://en.wikipedia.org/wiki/Biology"},{"name":"Transcription (genetics)","weight":0.577214,"wikipedia_article":"http://en.wikipedia.org/wiki/Transcription_(genetics)"},{"name":"Molecule","weight":0.565246,"wikipedia_article":"http://en.wikipedia.org/wiki/Molecule"},{"name":"Viral replication","weight":0.554797,"wikipedia_article":"http://en.wikipedia.org/wiki/Viral_replication"},{"name":"Liver cancer","weight":0.537308,"wikipedia_article":"http://en.wikipedia.org/wiki/Liver_cancer"},{"name":"Contraindication","weight":0.533638,"wikipedia_article":"http://en.wikipedia.org/wiki/Contraindication"},{"name":"DNA replication","weight":0.515945,"wikipedia_article":"http://en.wikipedia.org/wiki/DNA_replication"},{"name":"Invasiveness of surgical procedures","weight":0.495417,"wikipedia_article":"http://en.wikipedia.org/wiki/Invasiveness_of_surgical_procedures"},{"name":"Orders of magnitude (mass)","weight":0.485561,"wikipedia_article":"http://en.wikipedia.org/wiki/Orders_of_magnitude_(mass)"},{"name":"Enzyme inhibitor","weight":0.462025,"wikipedia_article":"http://en.wikipedia.org/wiki/Enzyme_inhibitor"},{"name":"Cancer staging","weight":0.42515,"wikipedia_article":"http://en.wikipedia.org/wiki/Cancer_staging"},{"name":"Hungary","weight":0.420539,"wikipedia_article":"http://en.wikipedia.org/wiki/Hungary"},{"name":"Boceprevir","weight":0.357215,"wikipedia_article":"http://en.wikipedia.org/wiki/Boceprevir"},{"name":"Transmission (medicine)","weight":0.334085,"wikipedia_article":"http://en.wikipedia.org/wiki/Transmission_(medicine)"},{"name":"Medical guideline","weight":0.329404,"wikipedia_article":"http://en.wikipedia.org/wiki/Medical_guideline"},{"name":"Telaprevir","weight":0.327745,"wikipedia_article":"http://en.wikipedia.org/wiki/Telaprevir"},{"name":"Injury","weight":0.289465,"wikipedia_article":"http://en.wikipedia.org/wiki/Injury"},{"name":"Complication (medicine)","weight":0.274684,"wikipedia_article":"http://en.wikipedia.org/wiki/Complication_(medicine)"},{"name":"Half-life","weight":0.0365852,"wikipedia_article":"http://en.wikipedia.org/wiki/Half-life"},{"name":"Socioeconomics","weight":0.0297972,"wikipedia_article":"http://en.wikipedia.org/wiki/Socioeconomics"},{"name":"Scientific consensus","weight":0.0271741,"wikipedia_article":"http://en.wikipedia.org/wiki/Scientific_consensus"},{"name":"Clearance (medicine)","weight":0.0168623,"wikipedia_article":"http://en.wikipedia.org/wiki/Clearance_(medicine)"},{"name":"Predictive medicine","weight":0.0168623,"wikipedia_article":"http://en.wikipedia.org/wiki/Predictive_medicine"},{"name":"Carbon","weight":0.0147415,"wikipedia_article":"http://en.wikipedia.org/wiki/Carbon"},{"name":"Time","weight":0.0147415,"wikipedia_article":"http://en.wikipedia.org/wiki/Time"},{"name":"Productivity","weight":0.0147415,"wikipedia_article":"http://en.wikipedia.org/wiki/Productivity"},{"name":"Segmentation (biology)","weight":0.0147415,"wikipedia_article":"http://en.wikipedia.org/wiki/Segmentation_(biology)"}]}
